Physician profile
Ben Rad
NPI 1063504249
$3,404.58
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2021: $326 · 2022: $1,282 · 2023: $1,059 · 2024: $32.16 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.77 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $470.06 | 2021-2025 | Wegovy, Saxenda |
| Amgen INC. | $385.67 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $314.95 | 2019-2022 | |
| Abbvie INC. | $311.64 | 2022-2023 | |
| Abbott Laboratories | $219.59 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $211.71 | 2022-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $149.56 | 2022 | |
| Neurocrine Biosciences, INC. | $140.00 | 2022 | |
| Daiichi Sankyo INC. | $124.98 | 2019 | |
| Mylan Specialty L.P. | $118.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.83 | 2023 | Jardiance |
| Becton, Dickinson and Company | $79.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.56 | 2023 | Verquvo |
| Corcept Therapeutics | $60.17 | 2025 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $48.61 | 2023 | Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $35.67 | 2022 | |
| Boston Scientific Corporation | $34.27 | 2025 | Wavewriter Alpha Prime 16 |
| Phadia US INC. | $16.40 | 2025 | Immunocap |
| Ironwood Pharmaceuticals, INC | $16.24 | 2022 | |
| Amarin Pharma, INC. | $14.92 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Rad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.